| 摘要 |
The present invention relates to the use of a histamine H4 agonist molecule, the enantiomers of 1-(7-amino-4,5,6-triethoxy-1-oxo-1,3-dihydro-3-isobenzofuranyl)-8- methoxy-2-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline or tritoqualine, for the treatment of the respiratory damage caused by cystic fibrosis and the reduction and prevention of bronchial superinfections. |
